NASDAQ:PDSB PDS Biotechnology (PDSB) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free PDSB Stock Alerts $2.99 +0.35 (+13.26%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$2.64▼$3.0050-Day Range$2.65▼$6.5952-Week Range$2.59▼$10.27Volume683,989 shsAverage Volume881,728 shsMarket Capitalization$109.67 millionP/E RatioN/ADividend YieldN/APrice Target$17.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get PDS Biotechnology alerts: Email Address PDS Biotechnology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside479.7% Upside$17.33 Price TargetShort InterestBearish16.77% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.04Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.55) to ($1.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.65 out of 5 starsMedical Sector846th out of 909 stocksPharmaceutical Preparations Industry395th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingPDS Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePDS Biotechnology has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.77% of the outstanding shares of PDS Biotechnology have been sold short.Short Interest Ratio / Days to CoverPDS Biotechnology has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in PDS Biotechnology has recently increased by 11.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPDS Biotechnology does not currently pay a dividend.Dividend GrowthPDS Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PDSB. Previous Next 1.7 News and Social Media Coverage News SentimentPDS Biotechnology has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for PDS Biotechnology this week, compared to 2 articles on an average week.Search InterestOnly 15 people have searched for PDSB on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows5 people have added PDS Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PDS Biotechnology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.00% of the stock of PDS Biotechnology is held by insiders.Percentage Held by InstitutionsOnly 26.84% of the stock of PDS Biotechnology is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for PDS Biotechnology are expected to decrease in the coming year, from ($1.55) to ($1.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PDS Biotechnology is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PDS Biotechnology is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPDS Biotechnology has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Bull ReportHealthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic About PDS Biotechnology Stock (NASDAQ:PDSB)PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Read More PDSB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PDSB Stock News HeadlinesApril 20, 2024 | finance.yahoo.comPDS Biotechnology Corporation (PDSB)April 5, 2024 | investing.comPDS Biotechnology Corp (PDSB)April 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.April 3, 2024 | msn.comLuminous quasar PDS 456 explored with MUSEMarch 30, 2024 | finance.yahoo.comPDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who hold 59% were hit as were institutionsMarch 29, 2024 | ca.style.yahoo.comTwitch online gamer Ninja says he has form of skin cancer in 'early stages'March 28, 2024 | finance.yahoo.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | finance.yahoo.comQ4 2023 PDS Biotechnology Corp Earnings CallApril 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.March 27, 2024 | finance.yahoo.comPDS Biotechnology Corp (PDSB) Reports Full Year 2023 Financial Results and Clinical Strategy UpdateMarch 27, 2024 | investorplace.comPDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023March 27, 2024 | globenewswire.comPDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial ResultsMarch 27, 2024 | msn.comPDS Biotechnology FY 2023 Earnings PreviewMarch 20, 2024 | globenewswire.comPDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial ResultsMarch 18, 2024 | msn.comMP: Authorities Grappling With Suspicious PDS Wheat Black MarketingMarch 17, 2024 | msn.comMP: Police Seize 30 Sacks Of PDS Rice Out For Black MarketingMarch 14, 2024 | msn.comGFA, PDS Ventures to invest $200,000 in new fashion innovatorsMarch 13, 2024 | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in March 2024March 13, 2024 | globenewswire.comPDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®January 26, 2024 | seekingalpha.comPDS Biotechnology: Advancement Of PDS0101 Continues With Expansion DataJanuary 23, 2024 | msn.comPDS Biotech names Kirk V. Shepard as Chief Medical OfficerJanuary 16, 2024 | finance.yahoo.comPDS Biotech to Participate at B. Riley Securities 4th Annual Oncology ConferenceJanuary 16, 2024 | finance.yahoo.comPDS Biotech to Participate at B. Riley Securities 4th Annual Oncology ConferenceJanuary 2, 2024 | finance.yahoo.comAll You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to BuyDecember 17, 2023 | ca.finance.yahoo.comPDSB Jan 2024 7.500 callDecember 16, 2023 | ca.finance.yahoo.comPDSB Jan 2024 7.500 putDecember 16, 2023 | ca.finance.yahoo.comPDSB Feb 2024 7.500 callSee More Headlines Receive PDSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/22/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PDSB CUSIPN/A CIK1472091 Webwww.pdsbiotech.com Phone(800) 208-3343Fax908-790-1212Employees25Year FoundedN/APrice Target and Rating Average Stock Price Target$17.33 High Stock Price Target$21.00 Low Stock Price Target$11.00 Potential Upside/Downside+479.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-138.44% Return on Assets-69.04% Debt Debt-to-Equity Ratio0.75 Current Ratio4.33 Quick Ratio4.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.84 per share Price / Book3.56Miscellaneous Outstanding Shares36,680,000Free Float33,011,000Market Cap$109.67 million OptionableOptionable Beta1.68 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Frank K. Bedu-Addo Ph.D. (Age 59)President, CEO & Director Comp: $854.1kMr. Lars Robert Boesgaard M.B.A. (Age 54)Principal Financial & Accounting Officer and CFO Dr. Joe J. DervanVP of Research & DevelopmentDr. Gregory L. Conn Ph.D. (Age 69)Chief Scientific Officer Comp: $220.46kMs. Deanne RandolphHead of Investor RelationsMr. Spencer Brown J.D. (Age 54)Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer Dr. Kirk V. Shepard M.D. (Age 72)Chief Medical Officer Ms. Janetta Trochimiuk (Age 61)Controller More ExecutivesKey CompetitorsEmergent BioSolutionsNYSE:EBSIO BiotechNASDAQ:IOBTCartesian TherapeuticsNASDAQ:RNACAnixa BiosciencesNASDAQ:ANIXCellectar BiosciencesNASDAQ:CLRBView All CompetitorsInstitutional OwnershipKathleen S. Wright Associates Inc.Bought 7,000 shares on 4/17/2024Ownership: 0.019%Inspirion Wealth Advisors LLCBought 18,383 shares on 4/13/2024Ownership: 0.968%Tower Research Capital LLC TRC Bought 7,612 shares on 2/13/2024Ownership: 0.029%Simplex Trading LLCBought 22,000 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions PDSB Stock Analysis - Frequently Asked Questions Should I buy or sell PDS Biotechnology stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PDSB shares. View PDSB analyst ratings or view top-rated stocks. What is PDS Biotechnology's stock price target for 2024? 4 Wall Street research analysts have issued twelve-month price objectives for PDS Biotechnology's shares. Their PDSB share price targets range from $11.00 to $21.00. On average, they expect the company's stock price to reach $17.33 in the next year. This suggests a possible upside of 479.7% from the stock's current price. View analysts price targets for PDSB or view top-rated stocks among Wall Street analysts. How have PDSB shares performed in 2024? PDS Biotechnology's stock was trading at $4.97 at the start of the year. Since then, PDSB stock has decreased by 39.8% and is now trading at $2.99. View the best growth stocks for 2024 here. When is PDS Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PDSB earnings forecast. How were PDS Biotechnology's earnings last quarter? PDS Biotechnology Co. (NASDAQ:PDSB) announced its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.05. What other stocks do shareholders of PDS Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other PDS Biotechnology investors own include Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Boxlight (BOXL), Otonomy (OTIC), Bionano Genomics (BNGO), CymaBay Therapeutics (CBAY), Cerecor (CERC), Enterprise Products Partners (EPD) and Evofem Biosciences (EVFM). Who are PDS Biotechnology's major shareholders? PDS Biotechnology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Inspirion Wealth Advisors LLC (0.97%) and Kathleen S. Wright Associates Inc. (0.02%). Insiders that own company stock include Delyle W Bloomquist, Matthew C Hill, Steve C Glover and Voorhees Seth Van. View institutional ownership trends. How do I buy shares of PDS Biotechnology? Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PDSB) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
